DRMA
$1.22
Post-MarketAs of Mar 17, 8:00 PM UTC
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications.
Historical Price
Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$1.22
Potential Downside
28421.9%
Whystock Fair Value$-345.53
Price
UndervaluedFair ValueOvervalued
Fundamentals
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product ca...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.90M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
0.08
Beta
Defensive asset. Lower volatility than the S&P 500.
0.60
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-203.36%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
4.20
Recent News
No recent news found.